| abstract |
Provided herein are oligomeric compounds with conjugate groups targeting apolipoprotein C-III (ApoCIII). In certain embodiments, the oligomeric compound targeting ApoCIII is conjugated to N-acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting ApoCIII for use in reducing ApoCIII to treat, prevent or ameliorate a disease, disorder or condition associated with ApoCIII. Certain diseases, disorders or conditions associated with ApoCIII include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein are useful for treating such diseases, disorders or conditions in an individual in need thereof. |